🇺🇸 Carboplatin Injection in United States
187 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 187
Most-reported reactions
- Febrile Neutropenia — 32 reports (17.11%)
- Dyspnoea — 30 reports (16.04%)
- Erythema — 21 reports (11.23%)
- Pruritus — 17 reports (9.09%)
- Vomiting — 17 reports (9.09%)
- Nausea — 16 reports (8.56%)
- Hypotension — 15 reports (8.02%)
- Diarrhoea — 14 reports (7.49%)
- Pyrexia — 13 reports (6.95%)
- Neutropenia — 12 reports (6.42%)
Other Oncology approved in United States
Frequently asked questions
Is Carboplatin Injection approved in United States?
Carboplatin Injection does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Carboplatin Injection in United States?
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the originator. The local marketing authorisation holder may differ — check the official source linked above.